Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 258Lung Neoplasms 207Adenocarcinoma of Lung 44Small Cell Lung Carcinoma 31Adenocarcinoma, Bronchiolo-Alveolar 23Brain Neoplasms 17Breast Neoplasms 14Neoplasm Metastasis 12Mesothelioma, Malignant 10Radiation Injuries 8Neoplasms 8Prostatic Neoplasms 7Melanoma 7Thymoma 6Squamous Cell Carcinoma of Head and Neck 6NSCLC 6Head and Neck Neoplasms 6Drug-Related Side Effects and Adverse Reactions 6Carcinoma, Renal Cell 6Pancreatic Neoplasms 4Esophageal Neoplasms 4Advanced NSCLC 4Urinary Bladder Neoplasms 3Salivary Gland Neoplasms 3Rectal Neoplasms 3Kidney Neoplasms 3Esthesioneuroblastoma, Olfactory 3Colorectal Neoplasms 3Carcinoma, Squamous Cell 3Thyroid Neoplasms 2

Interventions

Immunotherapy 2anlotinib 1Radiotherapy 1Drug Therapy 1Docetaxel 1Cisplatin 1Chemoradiotherapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Locally Advanced Non-small Cell Lung Cancer × Radiotherapy × Thoracic × Clear all
NCT05481775 2022-11-21

Evaluating Efficacy and Safety of Anlotinib Combined With Concurrent Chemoradiotherapy Followed by Consolidation Immunotherapy for Locally Advanced Non-small Cell Lung Cancer

Sun Yat-sen University

Phase 2 Withdrawn
Thoracic

Locally Advanced Non-small Cell Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡